Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$0.63 - $0.99 $5 - $8
-9 Reduced 7.69%
108 $0
Q2 2023

Aug 15, 2023

BUY
$0.77 - $1.16 $5 - $8
7 Added 6.36%
117 $0
Q1 2023

May 12, 2023

BUY
$0.91 - $2.63 $30 - $86
33 Added 42.86%
110 $0
Q4 2022

Feb 13, 2023

BUY
$0.8 - $8.05 $1 - $16
2 Added 2.67%
77 $0
Q3 2022

Nov 14, 2022

BUY
$1.39 - $9.94 $5 - $39
4 Added 5.63%
75 $0
Q2 2022

Aug 12, 2022

BUY
$1.47 - $2.94 $26 - $52
18 Added 33.96%
71 $0
Q1 2022

May 16, 2022

BUY
$2.72 - $5.97 $2 - $5
1 Added 1.92%
53 $0
Q3 2021

Nov 15, 2021

BUY
$4.2 - $11.92 $21 - $59
5 Added 10.64%
52 $0
Q1 2021

May 13, 2021

BUY
$4.3 - $7.48 $98 - $172
23 Added 95.83%
47 $0
Q4 2020

Feb 09, 2021

BUY
$4.25 - $8.14 $25 - $48
6 Added 33.33%
24 $0
Q3 2020

Nov 05, 2020

BUY
$4.65 - $9.45 $13 - $28
3 Added 20.0%
18 $0
Q2 2020

Aug 13, 2020

SELL
$2.0 - $6.62 $4 - $13
-2 Reduced 11.76%
15 $0
Q1 2020

May 14, 2020

BUY
$1.64 - $4.09 $27 - $69
17 New
17 $0

About Edesa Biotech, Inc.


  • Ticker EDSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,462,300
  • Market Cap $27.2M
  • Description
  • Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress s...
More about EDSA
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.